Reconceptualising risk-benefit analyses: the case of HIV cure research

Modern antiretroviral therapies (ART) are capable of suppressing HIV in the bloodstream to undetectable levels. Nonetheless, people living with HIV must maintain lifelong adherence to ART to avoid the re-emergence of the infection. So despite the existence and efficacy of ART, there is still substan...

Full description

Saved in:  
Bibliographic Details
Main Author: Steel, Robert (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2020
In: Journal of medical ethics
Year: 2020, Volume: 46, Issue: 3, Pages: 212-219
Online Access: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816162183
003 DE-627
005 20230428063531.0
007 cr uuu---uuuuu
008 220908s2020 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2019-105548  |2 doi 
035 |a (DE-627)1816162183 
035 |a (DE-599)KXP1816162183 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Steel, Robert  |e VerfasserIn  |4 aut 
109 |a Steel, Robert 
245 1 0 |a Reconceptualising risk-benefit analyses: the case of HIV cure research 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Modern antiretroviral therapies (ART) are capable of suppressing HIV in the bloodstream to undetectable levels. Nonetheless, people living with HIV must maintain lifelong adherence to ART to avoid the re-emergence of the infection. So despite the existence and efficacy of ART, there is still substantial interest in development of a cure. But HIV cure trials can be risky, their success is as of yet unlikely, and the medical gain of being cured is limited against a baseline of ART access. The medical prospect associated with participation in cure research thus look poor. Are the risks and burdens that HIV cure research places on participants so high that it is unethical, at present, to conduct it? In this paper, I answer ‘no’. I start my argument by describing a foundational way of thinking about the ethical justification for regulatory limits on research risk; I then apply this way of thinking to HIV cure trials. In offering this analysis, I confine my attention to studies enrolling competent adults and I also do not consider risks research may pose to third parties or society. Rather, my concern is to engage with the thought that some trials are so risky that performing them is an ethically unacceptable way to treat the participants themselves. I reject this thought and instead argue that there is no level of risk, no matter how high, that inherently mistreats a participant. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 46(2020), 3, Seite 212-219  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:46  |g year:2020  |g number:3  |g pages:212-219 
856 4 0 |u https://doi.org/10.1136/medethics-2019-105548  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/46/3/212.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185616139 
LOK |0 003 DE-627 
LOK |0 004 1816162183 
LOK |0 005 20220908053746 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#AACB3950CFA9AFC3993FBA04B65BB185B6998791 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw